CDK inhibitors as potential breast cancer therapeutics: New evidence for enhanced efficacy in ER+ disease

Breast Cancer Research

Volumn 11, Issue 6, 2009, Pages

  Sutherland, Robert L ^a,b   Musgrove, Elizabeth A ^a,b  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

6 ACETYL 8 CYCLOPENTYL 5 METHYL 2 [5 (1 PIPERAZINYL) 2 PYRIDINYLAMINO] 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; CYCLIN DEPENDENT KINASE INHIBITOR; ESTROGEN RECEPTOR; TAMOXIFEN; TRASTUZUMAB; 6 ACETYL 8 CYCLOPENTYL 5 METHYL 2 (5 PIPERAZIN 1 YLPYRIDIN 2 YLAMINO) 8H PYRIDO(2,3 D)PYRIMIDIN 7 ONE; 6-ACETYL-8-CYCLOPENTYL-5-METHYL-2-(5-PIPERAZIN-1-YLPYRIDIN-2-YLAMINO)-8H-PYRIDO(2,3-D)PYRIMIDIN-7-ONE; CDK4 PROTEIN, HUMAN; CDK6 PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE; ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE 4 INHIBITOR; CYCLIN DEPENDENT KINASE 6 INHIBITOR; LETROZOLE; PALBOCICLIB; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG;

BREAST CANCER; DRUG EFFICACY; DRUG INDICATION; DRUG TARGETING; EDITORIAL; ENZYME INHIBITION; HUMAN; BIOSYNTHESIS; BREAST TUMOR; DRUG ANTAGONISM; ENZYMOLOGY; FEMALE; METABOLISM; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RESISTANCE; CELL CYCLE REGULATION; CLINICAL TRIAL (TOPIC); CONCENTRATION RESPONSE; DRUG POTENTIATION; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; EVIDENCE BASED MEDICINE; TREATMENT RESPONSE;

BREAST NEOPLASMS; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE 6; FEMALE; HUMANS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIDINES; RECEPTORS, ESTROGEN;

EID: 77954571810     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2454     Document Type: Editorial

References (12)

1. Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai A, Ginther C, Atefi M, Chen I, Fowst C, Los G, Slamon DJ. PD 0332991 a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res 2009, 11:R77. 10.1186/bcr2419, 19874578, 2790859.
2. Arnold A, Papanikolaou A. Cyclin D1 in breast cancer pathogenesis. J Clin Oncol 2005, 23:4215-4224. 10.1200/JCO.2005.05.064, 15961768.
3. Sutherland RL, Musgrove EA. Cyclins and breast cancer. J Mammary Gland Biol Neoplasia 2004, 9:95-104. 10.1023/B:JOMG.0000023591.45568.77, 15082921.
4. Lee YM, Sicinski P. Targeting cyclins and cyclin-dependent kinases in cancer: lessons from mice, hopes for therapeutic applications in human. Cell Cycle 2006, 5:2110-2114.
5. Dickson MA, Schwartz GK. Development of cell-cycle inhibitors for cancer therapy. Curr Oncol 2009, 16:36-43. 2669234, 19370178.
6. Tetsu O, McCormick F. Proliferation of cancer cells despite CDK2 inhibition. Cancer Cell 2003, 3:233-245. 10.1016/S1535-6108(03)00053-9, 12676582.
7. Du J, Widlund HR, Horstmann MA, Ramaswamy S, Ross K, Huber WE, Nishimura EK, Golub TR, Fisher DE. Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. Cancer Cell 2004, 6:565-576. 10.1016/j.ccr.2004.10.014, 15607961.
8. Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, Albassam M, Zheng X, Leopold WR, Pryer NK, Toogood PL. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 2004, 3:1427-1438.
9. Baughn LB, Di Liberto M, Wu K, Toogood PL, Louie T, Gottschalk R, Niesvizky R, Cho H, Ely S, Moore MA, Chen-Kiang S. A novel orally active small molecule potently induces arrest in G1 primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6. Cancer Res 2006, 66:7661-7667. 10.1158/0008-5472.CAN-06-1098, 16885367.
10. Bosco EE, Wang Y, Xu H, Zilfou JT, Knudsen KE, Aronow BJ, Lowe SW, Knudsen ES. The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer. J Clin Invest 2007, 117:218-228. 10.1172/JCI28803, 1679964, 17160137.
11. Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 2009, 9:631-643. 10.1038/nrc2713, 19701242.
12. Watts CK, Brady A, Sarcevic B, deFazio A, Musgrove EA, Sutherland RL. Antiestrogen inhibition of cell cycle progression in breast cancer cells in associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation. Mol Endocrinol 1995, 9:1804-1813. 10.1210/me.9.12.1804, 8614416.